Ascendis Pharma A/S Company Profile (NASDAQ:ASND)

About Ascendis Pharma A/S (NASDAQ:ASND)

Ascendis Pharma A/S logoAscendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ASND
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.27536 billion
  • Outstanding Shares: 32,502,000
Average Prices:
  • 50 Day Moving Avg: $33.79
  • 200 Day Moving Avg: $33.79
  • 52 Week Range: $17.15 - $42.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.54
  • P/E Growth: -0.34
Sales & Book Value:
  • Annual Revenue: $3.64 million
  • Price / Sales: 313.14
  • Book Value: $4.68 per share
  • Price / Book: 7.49
  • EBITDA: ($105,450,000.00)
  • Net Margins: -2,977.70%
  • Return on Equity: -67.76%
  • Return on Assets: -60.93%
  • Current Ratio: 8.54%
  • Quick Ratio: 8.54%
  • Average Volume: 295,913 shs.
  • Beta: 0.71

Frequently Asked Questions for Ascendis Pharma A/S (NASDAQ:ASND)

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Friday, August, 18th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.24. The business earned $0.44 million during the quarter, compared to analysts' expectations of $0.78 million. Ascendis Pharma A/S had a negative net margin of 2,977.70% and a negative return on equity of 67.76%. The firm's revenue for the quarter was down 61.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.53) EPS. View Ascendis Pharma A/S's Earnings History.

When will Ascendis Pharma A/S make its next earnings announcement?

Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Wednesday, November, 29th 2017. View Earnings Estimates for Ascendis Pharma A/S.

Where is Ascendis Pharma A/S's stock going? Where will Ascendis Pharma A/S's stock price be in 2017?

6 brokerages have issued twelve-month price objectives for Ascendis Pharma A/S's stock. Their predictions range from $10.71 to $51.00. On average, they anticipate Ascendis Pharma A/S's share price to reach $36.95 in the next twelve months. View Analyst Ratings for Ascendis Pharma A/S.

What are analysts saying about Ascendis Pharma A/S stock?

Here are some recent quotes from research analysts about Ascendis Pharma A/S stock:

  • 1. According to Zacks Investment Research, "Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. " (8/23/2017)
  • 2. Wedbush analysts commented, "The Wedbush View. We see ASND as an attractive investment in the short- and longer-term with pipeline progress and competitor data release in the coming months, plus results from the pivotal heiGHt trial in late 2018. Cash runway into Q4:18. Ascendis reported revenues of €0.37MM and a (loss) of €(0.78)." (5/24/2017)
  • 3. Leerink Swann analysts commented, "We project that ASND’s cash position at YE16 will be ~ $180M and expect this will fund operations through completion of its TransCon Growth Hormone study in 2018." (12/1/2016)

Who are some of Ascendis Pharma A/S's key competitors?

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the folowing people:

  • Michael Wolff Jensen, Chairman of the Board, Senior Vice President, General Counsel
  • Jan Moeller Mikkelsen, President, Chief Executive Officer, Director
  • Scott T. Smith, Chief Financial Officer, Senior Vice President
  • Lotte Soenderbjerg, Senior Vice President, Chief Administrative Officer
  • Harald Rau, Senior Vice President, Chief Scientific Officer
  • Martin D. Auster M.D., Senior Vice President, Chief Business Officer
  • Flemming Steen Jensen, Senior Vice President, Product Supply
  • Grethe Rasmussen Ph.D., Senior Vice President, Product Development
  • Kennett Sprogoee Ph.D., Senior Vice President, Product Innovation
  • Peter Rasmussen, Vice President, Finance and Principal Financial and Accounting Officer

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

How do I buy Ascendis Pharma A/S stock?

Shares of Ascendis Pharma A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ascendis Pharma A/S's stock price today?

One share of Ascendis Pharma A/S stock can currently be purchased for approximately $35.07.

MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  189
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ascendis Pharma A/S (NASDAQ:ASND) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $36.95 (5.37% upside)
Consensus Price Target History for Ascendis Pharma A/S (NASDAQ:ASND)
Price Target History for Ascendis Pharma A/S (NASDAQ:ASND)
Analysts' Ratings History for Ascendis Pharma A/S (NASDAQ:ASND)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/28/2017Bank of America CorporationBoost Price Target$36.00 -> $46.00LowView Rating Details
9/22/2017Wells Fargo & CompanyReiterated RatingBuy$51.00HighView Rating Details
9/22/2017Credit Suisse GroupReiterated RatingOutperform$30.00 -> $50.00HighView Rating Details
9/22/2017WedbushReiterated RatingOutperform$65.00 -> $10.71HighView Rating Details
9/1/2017Leerink SwannReiterated RatingHold$28.00HighView Rating Details
5/11/2017J P Morgan Chase & CoInitiated CoverageOverweight$36.00LowView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for Ascendis Pharma A/S (NASDAQ:ASND)
Earnings by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)
Earnings History by Quarter for Ascendis Pharma A/S (NASDAQ ASND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/18/20176/30/2017($0.80)($1.04)$0.78 million$0.44 millionViewN/AView Earnings Details
5/23/2017Q1($0.64)($0.83)$1.10 million$0.40 millionViewN/AView Earnings Details
3/22/2017Q4($0.61)($0.55)$1.22 million$1.13 millionViewN/AView Earnings Details
11/30/2016Q316($0.71)($0.80)$1.25 million$1.30 millionViewN/AView Earnings Details
8/31/2016Q216($0.67)($0.60)$1.11 million$1.28 millionViewListenView Earnings Details
5/19/2016Q1($0.55)($0.90)$1.39 millionViewN/AView Earnings Details
4/14/2016Q4 2015($0.46)($0.54)$2.17 millionViewN/AView Earnings Details
8/24/2015Q2($0.48)($0.70)$2.23 million$2.15 millionViewN/AView Earnings Details
5/18/2015Q115($0.39)$0.07$2.24 million$2.38 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ascendis Pharma A/S (NASDAQ:ASND)
2017 EPS Consensus Estimate: ($3.19)
2018 EPS Consensus Estimate: ($3.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.68)($0.68)($0.68)
Q2 20172($0.82)($0.79)($0.81)
Q3 20172($0.91)($0.79)($0.85)
Q4 20172($0.92)($0.79)($0.86)
Q1 20181($0.83)($0.83)($0.83)
Q2 20181($0.84)($0.84)($0.84)
Q3 20181($0.85)($0.85)($0.85)
Q4 20181($0.87)($0.87)($0.87)
(Data provided by Zacks Investment Research)


Dividend History for Ascendis Pharma A/S (NASDAQ:ASND)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Ascendis Pharma A/S (NASDAQ:ASND)
No insider trades for this company have been tracked by


Headline Trends for Ascendis Pharma A/S (NASDAQ:ASND)
Latest Headlines for Ascendis Pharma A/S (NASDAQ:ASND)
Loading headlines, please wait.



Ascendis Pharma A/S (ASND) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.